Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Begg’s funnel plot for publication bias test. by Yupeng Luo (527348)

Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments by Stefania Ferro (76724)

“…The inhibition of tyrosinase (Ty, EC 1.14.18.1) represents an efficient strategy of decreasing melanogenesis and skin hyperpigmentation. …”

Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies by Brianna D. Mackie (9212677)

“…Its cell-permeable analogue <b>DC432</b> (IC₅₀ of 54 ± 4 nM) decreases the N-terminal methylation level of the regulator of chromosome condensation 1 and SET proteins in HCT116 cells. …”

Notch signaling regulates the responses of lipopolysaccharide-stimulated macrophages in the presence of immune complexes by Wipawee Wongchana (5367968)

“…A similar impact on IL-10 production was observed when Notch signaling was inhibited with a gamma-secretase inhibitor (GSI). …”

Effects of GSI treatment on MAPK, PI3K/AKT and NF-κB pathway activation in LPS/IC-activated macrophages. by Wipawee Wongchana (5367968)

“…The arrows indicate cells with decreased or no p50 nuclear translocation (green). …”

Liquid cultures in RPMI-1640. by Nicholas C. Schena (16541975)

Evaluation of Efficiency of Liposome-Entrapped Iridium(III) Complexes Inhibiting Tumor Growth In Vitro and In Vivo by Huiyan Hu (9376570)

“…Surprisingly, its liposome-entrapped complexes 3alip, 3blip, and 3clip on B16 cells showed strong cytotoxicity (IC₅₀ = 13.6 ± 2.8, 9.6 ± 1.1, and 18.9 ± 2.1 μM). …”

Estimated numbers of people aged 65+ years living with dementia under various scenarios and difference to ageing-only scenario. by Binod Nepal (625271)

Fig 1 - by Gilda Cennamo (448296)

“…</b> Left eye of a patient (50 years-old female) with pitituary adenoma before surgery reveals a reduction of vessel density in SCP (A1), DCP (B1), RPC (C1) and an increase of FAZ area (D1) respect to healthy subject. …”

DRP2B is partially required for flg22-induced endocytosis of FLS2. by John M. Smith (676719)

“…Representative maximum-intensity projection images and zoomed insets of FLS2-GFP fluorescence are shown, with bright pixels corresponding to increased abundance of FLS2-GFP at a given location. Scale bars = 10 µm. (D) Quantification of FLS2-GFP in puncta at 0, 35–45 or 50–60 min after elicitation with 1 µM flg22 indicates that loss of <i>DRP2B</i> resulted in ∼20% decrease in flg22-stimulated endocytosis of FLS2-GFP (35–45 min, P = 0.0204; 50–60 min, P = 0.0396). …”